These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 9007985)
1. Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Gale AJ; Sun X; Heeb MJ; Griffin JH Protein Sci; 1997 Jan; 6(1):132-40. PubMed ID: 9007985 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of thrombin formation by active site mutated (S360A) activated protein C. Nicolaes GA; Bock PE; Segers K; Wildhagen KC; Dahlbäck B; Rosing J J Biol Chem; 2010 Jul; 285(30):22890-900. PubMed ID: 20484050 [TBL] [Abstract][Full Text] [Related]
3. Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C. Mesters RM; Heeb MJ; Griffin JH Protein Sci; 1993 Sep; 2(9):1482-9. PubMed ID: 8401232 [TBL] [Abstract][Full Text] [Related]
4. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation. Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585 [TBL] [Abstract][Full Text] [Related]
5. A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Mesters RM; Heeb MJ; Griffin JH Biochemistry; 1993 Nov; 32(47):12656-63. PubMed ID: 8251484 [TBL] [Abstract][Full Text] [Related]
6. Gly74Ser mutation in protein C causes thrombosis due to a defect in protein S-dependent anticoagulant function. Chen C; Yang L; Villoutreix BO; Wang X; Ding Q; Rezaie AR Thromb Haemost; 2017 Jun; 117(7):1358-1369. PubMed ID: 28405673 [TBL] [Abstract][Full Text] [Related]
7. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Gale AJ; Xu X; Pellequer JL; Getzoff ED; Griffin JH Protein Sci; 2002 Sep; 11(9):2091-101. PubMed ID: 12192065 [TBL] [Abstract][Full Text] [Related]
8. The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Egan JO; Kalafatis M; Mann KG Protein Sci; 1997 Sep; 6(9):2016-27. PubMed ID: 9300501 [TBL] [Abstract][Full Text] [Related]
9. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Gale AJ; Heeb MJ; Griffin JH Blood; 2000 Jul; 96(2):585-93. PubMed ID: 10887122 [TBL] [Abstract][Full Text] [Related]
10. Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. Yang L; Bae JS; Manithody C; Rezaie AR J Biol Chem; 2007 Aug; 282(35):25493-500. PubMed ID: 17580306 [TBL] [Abstract][Full Text] [Related]
11. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Heeb MJ; Kojima Y; Hackeng TM; Griffin JH Protein Sci; 1996 Sep; 5(9):1883-9. PubMed ID: 8880912 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. Gale AJ; Tsavaler A; Griffin JH J Biol Chem; 2002 Aug; 277(32):28836-40. PubMed ID: 12063259 [TBL] [Abstract][Full Text] [Related]
13. Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by Gla domain-mutated human-activated protein C. Sun YH; Tran S; Norstrøm EA; Dahlbäck B J Biol Chem; 2004 Nov; 279(46):47528-35. PubMed ID: 15337738 [TBL] [Abstract][Full Text] [Related]
14. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa. Evenäs P; García de Frutos P; Nicolaes GA; Dahlbäck B Thromb Haemost; 2000 Aug; 84(2):271-7. PubMed ID: 10959700 [TBL] [Abstract][Full Text] [Related]
15. Conversion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. Rezaie AR; Esmon CT J Biol Chem; 1993 Sep; 268(27):19943-8. PubMed ID: 8104182 [TBL] [Abstract][Full Text] [Related]
16. Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. Yegneswaran S; Nguyen PM; Gale AJ; Griffin JH Thromb Haemost; 2009 Jan; 101(1):55-61. PubMed ID: 19132189 [TBL] [Abstract][Full Text] [Related]
17. Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity. Shen L; Villoutreix BO; Dahlbäck B Thromb Haemost; 1999 Sep; 82(3):1078-87. PubMed ID: 10494767 [TBL] [Abstract][Full Text] [Related]
18. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. Mosnier LO; Yang XV; Griffin JH J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulant dysfunction of human Arg352Trp-activated protein C caused by defective factor Va inactivation. Rintelen C; Yegneswaran S; Griffin JH Thromb Haemost; 2001 Feb; 85(2):274-9. PubMed ID: 11246547 [TBL] [Abstract][Full Text] [Related]
20. Regulation of factor V by the anticoagulant protease activated protein C: Influence of the B-domain and TFPIα. Ayombil F; Petrillo T; Kim H; Camire RM J Biol Chem; 2022 Nov; 298(11):102558. PubMed ID: 36183835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]